Sunil Sharma

Sunil Sharma, MD, FACP, MBA

Languages spoken: English, Hindi

Academic Information

Departments Adjunct - Molecular Pharmaceutics

Lab

Board Certification

  • Federal Licensing Examination

Research Interests

  • Clinical Trials, Phase I
  • Gastrointestinal Cancers
  • Targeted Drug Delivery Systems
  • Small Molecule Targeted Drug Discovery

Adjunct Professor, Pharmaceutics and Pharmaceutical Chemistry

Education History

Graduate Training University of Massachusetts
 MBA
University of Texas Health Science Center
 Fellow
Residency Michael Reese Hospital
 Resident
Michael Reese Hospital
 Intern
Residency Post Graduate Institute of Medical Education and Research
 Junior Resident
University of Delhi Hospital
 Intern
Professional Medical University of Delhi
 MD
Sardar Patel Vidyalaya
 AISSC

Selected Publications

Journal Article

  1. Fiskus W, Sharma S, Saha S, Shah B, Devaraj SG, Sun B, Horrigan S, Leveque C, Zu Y, Iyer S, Bhalla KN (2015). Pre-clinical efficacy of combined therapy with novel beta-catenin antagonist BC2059 and histone deacetylase inhibitor against AML cells. Leukemia, 29(6), 1267-78. (Read full article)
  2. Sharma S, Witteveen PO, Lolkema MP, Hess D, Gelderblom H, Hussain SA, Porro MG, Waldron E, Valera SZ, Mu S (2015). A phase I, open-label, multicenter study to evaluate the pharmacokinetics and safety of oral panobinostat in patients with advanced solid tumors and varying degrees of renal function. Cancer Chemother Pharmacol, 75(1), 87-95. (Read full article)
  3. Fiskus W, Sharma S, Shah B, Portier BP, Devaraj SG, Liu K, Iyer SP, Bearss D, Bhalla KN (2014). Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia, 28(11), 2155-64. (Read full article)
  4. Fiskus W, Sharma S, Qi J, Shah B, Devaraj SG, Leveque C, Portier BP, Iyer S, Bradner JE, Bhalla KN (2014). BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD. Mol Cancer Ther, 13(10), 2315-27. (Read full article)
  5. Krug LM, Wozniak AJ, Kindler HL, Feld R, Koczywas M, Morero JL, Rodriguez CP, Ross HJ, Bauman JE, Orlov SV, Ruckdeschel JC, Mita AC, Fein L, He X, Hall R, Kawabe T, Sharma S (2014). Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma. Lung Cancer, 85(3), 429-34. (Read full article)
  6. Sankar S, Theisen ER, Bearss J, Mulvihill T, Hoffman LM, Sorna V, Beckerle MC, Sharma S, Lessnick SL (2014). Reversible LSD1 inhibition interferes with global EWS/ETS transcriptional activity and impedes Ewing sarcoma tumor growth. Clin Cancer Res, 20(17), 4584-97. (Read full article)
  7. Ha K, Fiskus W, Choi DS, Bhaskara S, Cerchietti L, Devaraj SG, Shah B, Sharma S, Chang JC, Melnick AM, Hiebert S, Bhalla KN (2014). Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. Oncotarget, 5(14), 5637-50. (Read full article)
  8. Benson AB 3rd, Venook AP, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, Grem JL, Hunt S, Kamel A, Leong LA, Lin E, Messersmith W, Mulcahy MF, Murphy JD, Nurkin S, Rohren E, Ryan DP, Saltz L, Sharma S, Shibata D, Skibber JM, Sofocleous CT, Stoffel EM, Stotsky-Himelfarb E, Willett CG, Gregory KM, Freedman-Cass DA (2014). Colon cancer, version 3.2014. J Natl Compr Canc Netw, 12(7), 1028-59. (Read full article)
  9. Maison-Blanche P, Dakhil S, Baron A, Rottey S, Millard F, Daugaard G, Machiels JP, Conkright W, Sharma S, Soetekouw PM, Yachnin J, Sengelov L, Van Veldhuizen P, Agarwala SS, Semiond D, Chadjaa M, Shen L, Wade JL (2014). An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol, 73(6), 1241-52. (Read full article)
  10. Fiskus W, Sharma S, Qi J, Valenta JA, Schaub LJ, Shah B, Peth K, Portier BP, Rodriguez M, Devaraj SG, Zhan M, Sheng J, Iyer SP, Bradner JE, Bhalla KN (2014). Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Mol Cancer Ther, 13(5), 1142-54. (Read full article)
  11. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Lau YY, Goldwasser M, Boral AL, Engelman JA (2014). Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med, 370(13), 1189-97. (Read full article)
  12. Bendell JC, Gordon MS, Hurwitz HI, Jones SF, Mendelson DS, Blobe GC, Agarwal N, Condon CH, Wilson D, Pearsall AE, Yang Y, McClure T, Attie KM, Sherman ML, Sharma S (2014). Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of dalantercept, an activin receptor-like kinase-1 ligand trap, in patients with advanced cancer. Clin Cancer Res, 20(2), 480-9. (Read full article)
  13. Patel JD, Krilov L, Adams S, Aghajanian C, Basch E, Brose MS, Carroll WL, de Lima M, Gilbert MR, Kris MG, Marshall JL, Masters GA, ODay SJ, Polite B, Schwartz GK, Sharma S, Thompson I, Vogelzang NJ, Roth BJ (2014). Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol, 32(2), 129-60. (Read full article)

Abstract

  1. Shaw AT, Camidge DR, Felip E, Sharma S, Tan DSW, Kim DW, De Pas T, Vansteenkiste JF, Santor A, Liu G, Chow L, Goldwasser M, Lau Y, Boral AL, Mehra R (2012). Results of the first-in-human Phase I study of the ALK inhibitor LDK378 in advanced malignancies [Abstract]. Oral presentation ESMO Congress.
  2. Wade JL, Dakhil SR, Baron AD, Rottey S, Millard FE, Daugaard G, Machiels J, Conkright WA, Sharma S, Soetekouw P, Yachnin J, Sengelv L, van Veldhuizen P, Agarwala SS, Quyen Nguyen TX, Chadjaa M, Maison-Blanche P (2012). A QTc study of cabazitaxel in patients with advanced solid tumors [Abstract]. Poster ASCO Genitourinary Cancers Symposium.

Patent

  1. Vankayalapati H, Sorna V, Warner SL, Bearss DJ, Sharma S (2016). Substituted N-(3(Pyrimidin-4-YL)Phenyl)Acrylamide Analogs as Tyrosine Receptor Kinase BTK Inhibitors. U.S. Patent No. US 9,296,703, B2. Washington, D.C.:U.S. Patent and Trademark Office.
  2. Bearss D, Vankayalapati H, Sorna V, Warner S, Sharma S (2015). “Substituted N-(3-(Pyrimidin-4-YL)Phenyl)Acrylamide Analogs as Tyrosine Receptor Kinase BTK Inhibitors”. U.S. Patent No. 9,206,176. Washington, D.C.:U.S. Patent and Trademark Office.
  3. Vankayalapati H, Sorna V, Warner S, Stephens B, Bearss D, Sharma S (2015). Substituted (E)-N'-(1-Phenylethylidene)Benzohydrazide Analogs as Histone Demethylase Inhibitors”. U.S. Patent No. 8,987,335. Washington, D.C.:U.S. Patent and Trademark Office.
  4. Bearss D, Vankayalapati H, Mollard A, Warner S, Sharma S (2014). Substituted N-Phenylpyrimidin-2-Amine Analogs as Inhibitors of the AXL Kinase. U.S. Patent No. 8,901,120. Washington, D.C.:U.S. Patent and Trademark Office.
  5. Bearss D, Vankayalapati H, Sorna V, Warner S, Sharma S (2012). “Substituted 3-(IH-Benzo[D]Imidazol-2-YL)-IH-Indazole Analogs as Inhibitors of the PDKI Kinase”. U.S. Patent No. WO 2012135799 A1 20121004. Washington, D.C.:U.S. Patent and Trademark Office.